Table 2.

Patient characteristics by PFS and overall survival OS

n2-Year PFS (%; 95% CI)P value2-Year OS (%; 95% CI)P value
Overall549 (1–17)19 (7–31)
AgeAge 17 years or younger2914 (2–26)0.130 (12–48)0.07
Age 18 years or older254 (0–12)5 (0–15)
GenderFemale264 (0–12)0.19 (0–21)0.1
Male2814 (0–28)29 (9–49)
Tumor locationThoracic313 (0–9)0.0415 (1–29)0.1
Head/neck1916 (0–32)27 (2–52)
Other locations425 (0–68)25 (0–68)
Tumor histologyCarcinoma with squamous differentiation2114 (0–30)0.433 (9–57)0.2
Carcinoma without squamous differentiation234 (0–12)6 (0–18)
Other histology911 (0–33)22 (0–49)
NUT translocationBRD4-NUT388 (0–12)0.112 (0–24)0.4
BRD3-NUT3033 (0–86)
NUT-variant1217 (0–39)33 (6–60)
MetastasesNo metastases2119 (1–37)0.0425 (3–37)0.1
Metastases323 (0–9)16 (2–26)
Lymph nodeNo involvement2910 (0–22)0.320 (2–38)0.3
involvementInvolvement258 (0–18)18 (2–34)
Extent of surgical resectionLess than gross total1010 (0–30)0.0144 (7–81)0.03
Complete560 (17–100)80 (45–100)
Less than gross total or no surgical resection494 (0–10)0.00112 (0–24)0.002
Complete560 (17–100)80 (45–100)
Initial radiotherapyNo270<0.00015 (0–15)0.0003
Yes2619 (3–35)35 (13–57)
Chemotherapy regimenPlatinum-based339 (0–19)0.622 (4–40)0.3
Other2010 (0–24)15 (0–31)
Anthracycline/alkylator-based1718 (0–36)0.628 (4–40)0.4
Other366 (0–14)15 (1–29)